Rapport Therapeutics (RAPP) Change in Accured Expenses (2023 - 2026)
Rapport Therapeutics (RAPP) has 4 years of Change in Accured Expenses data on record, last reported at -$3.5 million in Q1 2026.
- On a quarterly basis, Change in Accured Expenses fell 1154.68% to -$3.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.3 million, a 349.9% increase, with the full-year FY2025 number at $6.2 million, up 1561.99% from a year prior.
- Change in Accured Expenses reached -$3.5 million in Q1 2026 per RAPP's latest filing, down from $3.7 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for RAPP hit a ceiling of $3.7 million in Q4 2025 and a floor of -$3.5 million in Q1 2026.
- A 4-year average of $684363.6 and a median of $453000.0 in 2025 define the central range for Change in Accured Expenses.
- Peak YoY movement for Change in Accured Expenses: skyrocketed 433.33% in 2025, then crashed 1154.68% in 2026.
- Tracing RAPP's Change in Accured Expenses over 4 years: stood at $3.4 million in 2023, then plummeted by 74.89% to $848000.0 in 2024, then soared by 334.67% to $3.7 million in 2025, then plummeted by 194.71% to -$3.5 million in 2026.
- Business Quant data shows Change in Accured Expenses for RAPP at -$3.5 million in Q1 2026, $3.7 million in Q4 2025, and $1.7 million in Q3 2025.